Mark Alles

Mark Alles serves as Celgene's chief executive officer. He assumed the role on March 1, 2016. Previously he served as president and chief operating officer. Alles served as executive vice president and global head of hematology and oncology from December 2012 until July 2014, following his promotion to executive vice president and chief commercial officer in February 2012. Alles joined Celgene in April 2004 and served as vice president, global marketing, until March 2009 when he became president of the Americas region. Responsibility for commercial operations in Japan and the Asia Pacific region was added in July 2011. Alles previously served as vice president for the U.S. Oncology Business Unit of Aventis Pharmaceuticals and in other commercial sales and marketing management roles over an 11-year period with Aventis. After earning his B.S. degree from Lock Haven University of Pennsylvania and serving as a captain in the United States Marine Corps, Alles began his 29-year career in the pharmaceutical industry at Bayer.

Mr. Mark J. Alles has been the Chief Executive Officer of Celgene Corporation since March 1, 2016. Mr. Alles served as the President and Chief Operating Officer of Celgene Corporation (also know as Celgene Inc.) and Celgene Limited from August 1, 2014 to March 1, 20160. He served as an Executive Vice President of Celgene Corporation since February 15, 2012 until August 1, 2014 and also served as its Global Head of Hematology & Oncology since December 2012 until August 1, 2014. He served as the Chief Commercial Officer at Celgene Corporation since February 15, 2012. He serves as the Chief Commercial Officer of Celgene Corporation. He joined Celgene in April 2004 and served as Vice President of Global Marketing until March 2009 when he became President of the Americas Region. Responsibility for commercial operations in Japan and the Asia Pacific Region was added in July 2011. Prior to joining Celgene, Mr. Alles served as Vice President for the US Oncology Business Unit of Aventis Pharmaceuticals and in other commercial sales and marketing management roles over an 11 year period with Aventis. He serving as a Captain in the United States Marine Corps, he started his 25-year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. He has been a Director of Celgene Corporation since February 11, 2016. He serves as a Director for Gilda’s Club NYC, a not-for-profit organization helping people with cancer. He serves as a Trustee of The Healthcare Institute of New Jersey. Mr. Alles served as an Observer of Acetylon Pharmaceuticals, Inc., since February 9, 2012. Mr. Alles has B.S. degree from Lock Haven University of Pennsylvania.